Portal de investigación
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Martínez-Campreciós J
- Riveiro-Barciela M
- Muñoz-Gómez R
- Londoño MC
- Roget M
- Serra MÁ
- Escudero-García D
- Purchades L
- Rodríguez M
- Losa-García JE
- Gutiérrez ML
- Carmona I
- García-Samaniego J
- Morano L
- Martín-Granizo I
- Delgado M
- Ramos N
- Azancot MA
- Rodríguez-Frías F
- Buti M
Grupos
Abstract
BACKGROUND AND AIM: Patients with chronic kidney disease (CKD) and hepatitis C infection can be safely and effectively treated with direct-acting antivirals (DAAs). However, there is scarce data on the long-term impact of hepatitis C cure on CKD. The aim of this study was to assess the long-term mortality, morbidity and hepatic/renal function outcomes in a cohort of HCV-infected individuals with CKD treated with DAAs. METHODS: 135 HCV patients with CKD stage 3b-5 who received ombitasvir/paritaprevir/ritonavir±dasabuvir in a multicenter study were evaluated for long-term hepatic and renal outcomes and their associated mortality. RESULTS: 125 patients achieved SVR and 66 were included. Prior to SVR, 53 were under renal replacement therapy (RRT) and 25 (37.8%) had liver cirrhosis. After a follow-up of 4.5 years, 25 (38%) required kidney transplantation but none combined liver-kidney. No changes in renal function were observed among the 51 patients who did not receive renal transplant although eGFR values improved in those with baseline CKD stage 3b-4. Three (5.6%) subjects were weaned from RRT. Eighteen (27.3%) patients died, mostly from cardiovascular events; 2 developed liver decompensation and 1 hepatocellular carcinoma. No HCV reinfection was observed. CONCLUSIONS: Long-term mortality remained high among end-stage CKD patients despite HCV cure. Overall, no improvement in renal function was observed and a high proportion of patients required kidney transplantation. However, in CKD stage 3b-4 HCV cure may play a positive role in renal function.
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0210-5705, 0210-5705
- Tipo:
- Article
- Páginas:
- 594-602
- PubMed:
- 36584754
- Factor de Impacto:
- 0,280 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Gastroenterologia y Hepatologia ELSEVIER ESPANA SLU
Documentos
- No hay documentos
Filiaciones
Keywords
- Antivirales de acción directa; Chronic kidney disease; Direct-acting antivirals; Enfermedad renal crónica; Hepatitis C; Kidney transplantation; Trasplante renal
Campos de Estudio
Cita
Martínez J,Riveiro M,Muñoz R,Londoño MC,Roget M,Serra MÁ,Escudero D,Purchades L,Rodríguez M,Losa JE,Gutiérrez ML,Carmona I,García J,Morano L,Martín I,MONTERO M,PRIETO M,Delgado M,Ramos N,Azancot MA,Rodríguez F,Buti M. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. Gastroenterol. Hepatol. 2023. 46. (8):p. 594-602. IF:2,200. (3).